Tanfac's capex plan tripled. Funding mix changed. No reconciliation offered.
Management increased total capex guidance from ₹500-700 cr to ₹1,500-1,700 cr over four years, and altered the R-32 funding mix from ₹300 cr QIP+debt to ₹250 cr QIP plus preferential issue, without bridging either discrepancy.
What's new
- Tanfac is net debt-free after completing a ₹250 cr QIP.
- HFC-32 plant is ~60% complete, targeting commissioning by end-Q3 FY27.
- Q1 FY27 revenue ₹187 cr (+6.3% YoY), EBITDA ₹28.6 cr (-1.4%), margin 15.3%.
- Solar grade DHF plant is at full capacity, with ~80% volume under long-term contracts.
Themes from the call
Demand
Solar grade DHF running at full capacity; HFC-32 already ~65% contracted at $5.5/kg for 5-7 years.
Margins
EBITDA margin fell to 15.3% due to temporary sulfur, power and fuel cost pressures; management expects improvement to 16-19% from Q2 FY27.
Capital allocation
Massive capex plan of ₹1,500-1,700 cr over 4 years across AHF, electronic grade and fluoropolymers, funded by equity (QIP, preferential) and debt-free balance sheet.
Guidance watch
- FY27 revenue growth at least 30%, driven by HFC-32 launch and existing product utilisation.
- FY28 revenue growth above 60% on new project ramp-up.
- EBITDA margin: FY27 blended 21-22%, FY28 ~25% post HFC-32.
- HFC-32 utilisation: 65-70% in Q4 FY27, 80-85% in FY28; management also cited 90%+ in the coming year (discrepancy).
Risk flags
- Capex guidance tripled without reconciliation; investors need to understand the base and phasing.
- R-32 funding mix changed; the previous ₹300 cr QIP+debt plan was abandoned for a smaller QIP plus preferential, with no explanation for the gap.
- HFC-32 ramp-up critical to FY27/FY28 targets; any delay in commissioning (target end-Q3) or stabilisation (Dec-Jan) could hit guidance.
- Sulfur cost pass-through with 30-45 day lag could keep margins volatile.
Key quotes
-
"Tanfac today is net debt-free, providing us with significant financial flexibility to prosecute our next phase of expansion while maintaining a prudent balance sheet."
— Afzal Malkani, Managing Director, prepared remarks -
"Over the next 4 years, the total CapEx across all phases will be in the range of 1,500 to 1,700 crores."
— Tanfac management, Jul 2026 call
The brief
Tanfac Industries reported a resilient quarter: revenue up 6.3% to ₹187 cr, solar DHF at full capacity, and a net debt-free balance sheet after a ₹250 cr QIP. But the real story is on the call: the capital plan has ballooned. In May management said ₹500-700 cr over 3-5 years for the next expansion after R-32. Now that number is ₹1,500-1,700 cr over 4 years, roughly triple the earlier range with no reconciliation. The funding mix for R-32 has also shifted. The ₹300 cr QIP-plus-term-debt plan is gone; instead, a ₹250 cr QIP and a proposed ₹100 cr preferential issue funded the project, leaving a gap that management did not explain. These inconsistencies cut against the otherwise confident tone. On HFC-32, the 20,000-tonne plant is 60% complete, with 65% capacity contracted at $5.5/kg. Revenue guidance of ₹900-1,000 cr and 30% EBITDA margins are ambitious but hinge on a tight commissioning timeline. Management also gave two different utilisation numbers (65-70% in Q4 FY27 and 90%+ in the coming year) without resolving the inconsistency. The broader plan to move up the fluorochemical value chain (electronic grade, fluoropolymers, HFOs) looks promising but remains years away. For now, the gap between past guidance and present numbers is the dominant signal. Investors should press for a clear bridge on capex and funding before underwriting the growth story.
Tanfac's capital plan has tripled and its funding story has changed. Without a bridge, guidance is harder to trust.